Articles tagged with Glioma Cells
Researchers have created a 3D experimental system to study the response of low-grade gliomas to drugs, providing a more realistic environment for testing treatments. The system uses organoids from pluripotent stem cells to replicate glioma development and characteristics.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
A new study from the CUNY Graduate Center uncovers key mechanisms responsible for the transformation of adult progenitor cells into brain tumors. Researchers found that a specific combination of genetic mutations and growth factor overproduction drives this transformation, highlighting the importance of epigenetic changes in glioma dev...
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
Researchers discovered a novel mechanism for miR-10b activation in high-grade gliomas, implicating topologic reorganization of chromatin and long-non-coding RNAs. This finding suggests new RNA-targeted strategies for glioma therapy and points to the vulnerability of tumor-initiating cells.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Researchers at Weill Cornell Medicine have profiled individual cells from patients' brain tumors in unprecedented detail, revealing distinct states and programming marks that could be targeted with future drugs. The study offers insights into glioma dynamics and may lead to better detection, staging, monitoring, and treatment methods.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers have developed poly-ion complex (PIC) nanomicelles loaded with CPT1A inhibitors to deliver drugs into brain cells, reducing fatty acid oxidation and improving treatment for glioblastoma. The delivery system successfully increased cellular concentration of the cargo and biological activity.
A novel gene therapy has been developed to convert glioma cells into functional neurons, offering a new approach to treating the disease. This technology may prolong treatment time by arresting rapid proliferation of malignant glioma cells.
Artificial brains, called organoids, are created using traditional Japanese flower arranging techniques, providing a more authentic model for studying brain tumours and their growth. The technique enables researchers to test hundreds of different chemical combinations on patient cells to identify promising treatment options.
Researchers at MD Anderson Cancer Center identified a pathway by which cancer cells spread in the brain, opening up new possibilities for treatment. They found that the gene WNT5A enables glioma stem cells to transition into GdECs, leading to aggressive tumor growth and disease recurrence.
Research reveals that childhood brain tumors originating from undifferentiated stem cells are more frequent and aggressive than those from oligodendrocyte precursor cells. Tumor cells from stem cells also show increased susceptibility to cancer drugs, according to a new study published in Cancer Research.
A widely used brain cancer cell line, U87MG, has been found to be of unknown origin and different from the original patient tumor. Researchers used forensic and mitochondrial DNA profiling to trace the cell line's origin, revealing a potential mix-up or cross-contamination.
Scientists at Newcastle University have made a groundbreaking discovery that brain tumour cells use fats to make energy, not sugars as previously believed. This new understanding has significant implications for developing treatments for glioma, the most common form of primary malignant brain tumour.
Researchers reveal brain cancer's highly organized structure, with glioma cells forming streams, swirls, and spheres to protect and spread tumor growth. These structures are not related to specific cancer mutations and can be targeted for treatment.
Researchers at UC Davis have discovered a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. This mechanism was found to be effective against glioma cells, which are responsible for a usually fatal type of brain cancer, and could be applicable to other highly aggressive cancers.
Researchers are developing an irreversible electroporation technique to target and destroy therapy-resistant cells in glioblastoma. The treatment has shown success in animal trials and is now being tested on human cells.
A team of engineers has developed a three-dimensional hydrogel that more closely mimics the properties of brain tissues, allowing researchers to selectively tune up or down the malignancy of cancer cells. By adding hyaluronic acid, they found that glioma cells exhibited reduced or enhanced malignancy in different materials.
A multi-institutional team of researchers pinpointed the genetic traits of cells giving rise to gliomas, a common form of malignant brain cancer. They identified a core set of genes and pathways dysregulated during tumor progression, providing rich new potential targets for therapeutic intervention.
Researchers found that downregulation of CD97 gene expression by suppressing Wilms tumor 1 protein results in reduced cellular invasiveness exhibited by glial tumor cells, correlating with glioma cell invasiveness and proposed as a new target for anti-glioma therapies.
A University of Oregon-led team has identified oligodendrocyte precursor cells (OPCs) as the cellular origin of malignant glioma, a deadly human brain cancer. The discovery was made possible by a genetic mosaic technique that allowed researchers to pinpoint the point of origin for tumor development.
Rafael Davalos has developed a method to treat cancerous tumors using irreversible electroporation, achieving complete remission in a seven-year-old dog. He aims to explore its potential in treating other pathologies, such as cardiac arrhythmias and glioblastoma multiforme.
Researchers at UAB have discovered that blocking a specific receptor on glioma cells can starve them of nutrients, effectively stopping their invasion in the brain. The target is a drug already approved for use in Europe, which increases blood vessel size.
Researchers discovered that glioma cells use microglia, the brain's immune cells, to grow and expand rapidly. By manipulating microglial cells' receptors, gliomas can clear the way for further growth.
Researchers discovered a novel compound, PI-103, that cooperatively inhibits both p110α subunit of PI3 kinase and downstream molecule mTOR. This dual inhibition shows high effectiveness against human gliomas in mice without toxicity.
Researchers found that marrow-derived neural stem-like cells genetically engineered to produce interleukin-23 can track and destroy glioma cells, providing long-term immunity. This discovery offers a promising new therapeutic option for treating brain tumors.
Researchers have genetically altered a herpes simplex virus to selectively target and kill malignant glioma cells, with promising results in mouse studies. The modified virus can extend the lives of animals with implanted human gliomas by several days.
Researchers discovered a peptide antigen that targets glioblastoma multiforme, a highly aggressive brain tumor. The immune system recognizes this antigen, triggering an immune response and potentially leading to longer patient survival.
Glioma cells induce angiogenesis by interacting with host vasculature and sprouting new vessels, defying the cooptation model. Vascular outgrowth occurs as a continuous process of growth and remodeling, starting early in tumor progression.